Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20170529

    		SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200056 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    		Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20200056

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid
    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester
    Title:

    A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
    Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201402 - Ezenwajiaku Nkiruka

  • Investigator:
    Nkiruka Ezenwajiaku
    RCname Email

    		Coordinator:

    IRB: 20201402

    		SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Pancreas
    Sponsor: ETCTN

    Enrolling Sites:

    Sylvester
    Title:

    A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
    Eligibility Criteria - NCT03816358 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201359 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    		Coordinator:
    RCemailImg Carla Montoya

    IRB: 20201359

    		SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Esophagus,Stomach
    Sponsor: ETCTN

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
    Eligibility Criteria - NCT03641313 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220046 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    		Coordinator:
    RCemailImg Natalia Sanders Branca
    RCphone +1 (305) 2433781

    IRB: 20220046

    		SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Stomach
    Sponsor: ETCTN

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) with or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
    Eligibility Criteria - NCT04941287 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    		SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue
    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    Title:

    Molecular Analysis for Therapy Choice (MATCH)
    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • RTX-240-01 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200686

    		SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Multiple
    Sponsor: Rubius Therapeutics

    Enrolling Sites:

    Sylvester
    Title:

    PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB
    Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"

  • Tbio-6517-ITu-001 - Pimentel, Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20200277

    		SDG: Colorectal Cancer
    Disease Site(s):

    Multiple
    Sponsor: TSB

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors
    Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220162 - Spieler Benjamin

  • Investigator:
    Benjamin Spieler
    RCname Email

    		Coordinator:
    RCemailImg Zaida Abreu
    RCphone +1 (305) 2434243

    IRB: 20220162

    		SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Esophagus
    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
    Eligibility Criteria - NCT03801876 *This information has been extracted from " www.clinicaltrials.gov"

  • SPN-00714 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    		Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20190673

    		SDG: Other
    Disease Site(s):

    Breast,Colon,Esophagus,Kidney,Lung,Other Female Genital,Ovary,Stomach
    Sponsor: MTEM

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors
    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"